Compare FFIC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | TRDA |
|---|---|---|
| Founded | 1929 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.6M | 500.4M |
| IPO Year | 1996 | 2021 |
| Metric | FFIC | TRDA |
|---|---|---|
| Price | $15.96 | $6.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $16.80 | ★ $21.00 |
| AVG Volume (30 Days) | 193.4K | ★ 603.9K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ 151.43 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $7,455,000.00 | ★ $25,421,000.00 |
| Revenue This Year | $14.57 | $39.97 |
| Revenue Next Year | $6.64 | $50.80 |
| P/E Ratio | $93.76 | ★ N/A |
| Revenue Growth | ★ 7.31 | N/A |
| 52 Week Low | $11.13 | $4.93 |
| 52 Week High | $17.79 | $16.45 |
| Indicator | FFIC | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 33.80 |
| Support Level | $15.56 | $5.58 |
| Resistance Level | $16.58 | $6.90 |
| Average True Range (ATR) | 0.32 | 0.81 |
| MACD | 0.01 | -0.28 |
| Stochastic Oscillator | 63.36 | 9.70 |
Flushing Financial Corp is a bank holding company. Through its subsidiary, the company is engaged in attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, mainly in originations and purchases of multi-family residential properties loans, commercial business loans, commercial real estate mortgage loans and, to a lesser extent, one-to-four family loans (focusing on mixed-use properties, which are properties that contain both residential dwelling units and commercial units). It also operates an internet branch, under the brands of iGObanking.com and BankPurely. The company operates as a single unit, a community bank.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.